Revolutionising Cardio-Oncology Care with Precision Genomics

Area of Science:

• Cardio-oncology
• Precision Medicine
• Genomics

Background:

• Cardiovascular disease is a leading cause of mortality in cancer survivors, often linked to anticancer therapy cardiotoxicity.
• Precision cardio-oncology aims to mitigate these risks through advanced genetic insights.

Purpose of the Study:

• To explore advancements in precision cardio-oncology, focusing on genetic testing, therapeutics, and their clinical impact.
• To demonstrate the benefits of integrating precision genomics in individualized cancer patient care.

Main Methods:

• Review of progress in genetic testing and therapeutics for cardio-oncology.
• Case studies illustrating precision genomics in managing cancer-therapy-related cardiac dysfunction, clonal hematopoiesis, and polygenic risk.
• Leveraging real-world genomic data and human-induced pluripotent stem cells for risk stratification and understanding regulatory RNAs.

Main Results:

• Precision genomics enables better risk assessment, diagnosis, and personalized, cost-effective therapeutics in cardio-oncology.
• Genomic data advances understanding of noncoding RNAs (long noncoding RNAs and microRNAs) in cardiovascular health.
• Human-induced pluripotent stem cells offer a promising model for precision cardio-oncology risk stratification.

Conclusions:

• Significant progress in genetic approaches for cardio-oncology necessitates evolving regulatory oversight and provider education.
• Integrating genetic applications into electronic medical records can provide crucial point-of-care clinical decision support.
• Ensuring confidence in diverse populations for genetic studies is vital for comprehensive understanding and effective clinical applications.